A Study of CCCTC-binding Factor (CTCF) in Infantile Hemangiomas

This study has been withdrawn prior to enrollment.
(no subjects were enrolled, study was halted due to study staff departure)
Information provided by (Responsible Party):
Yale University
ClinicalTrials.gov Identifier:
First received: September 9, 2009
Last updated: June 23, 2014
Last verified: June 2014
The purpose of this study is to evaluate the genotype of CTCF, a proven transcription factor, in patients with infantile hemangiomas and to monitor tumor growth. The investigators aim to determine whether or not the CTCF genotype might serve as an early and reliable predictor of tumor growth.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Infantile Hemangioma Tumor Size and C/T Polymorphism Within CTCF Binding Site Six

Resource links provided by NLM:

Further study details as provided by Yale University:

Biospecimen Retention:   Samples With DNA
Over the course of the study, one blood draw will be performed on each patient. This blood will be used for genetic analysis.

Enrollment: 0
Study Start Date: September 2009
Study Completion Date: June 2012
Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Patients with Infantile Hemangiomas

Detailed Description:
This study seeks to examine a potential relationship between CTCF genotype and hemangioma size and growth rate. In addition to the initial visit, patients will return to our clinic for evaluation at two weeks, one month, two months, six months, and one year. At each visit, patients' hemangiomas will be measured and photographed. At one point over the course of evaluation, a blood sample will be taken from each patient for evaluation of C/T polymorphism at CTCF binding site six.

Ages Eligible for Study:   up to 1 Year
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients to be recruited will include infants with hemangiomas on any part of their body.

Inclusion Criteria:

  • Hemangioma must appear within one month prior to enrollment

Exclusion Criteria:

  • Hemangioma appeared before one month prior to enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00974129

United States, Connecticut
Yale Dermatology Associates
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
Principal Investigator: Deepak Narayan, MD Yale University
  More Information

Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT00974129     History of Changes
Other Study ID Numbers: 0507000430  Yale-0430 
Study First Received: September 9, 2009
Last Updated: June 23, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Hemangioma, Capillary
Port-Wine Stain
Congenital Abnormalities
Neoplasms by Histologic Type
Neoplasms, Vascular Tissue
Skin Abnormalities
Skin Diseases

ClinicalTrials.gov processed this record on May 24, 2016